89bio Inc. (ETNB)
6.06
0.17 (2.89%)
At close: Apr 17, 2025, 3:59 PM
6.14
1.32%
After-hours: Apr 17, 2025, 06:48 PM EDT
Company Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.
Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis.
The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
89bio Inc.
| Country | United States |
| IPO Date | Nov 11, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 93 |
| CEO | Rohan Palekar |
Contact Details
Address: 142 Sansome Street San Francisco, California United States | |
| Website | https://www.89bio.com |
Stock Details
| Ticker Symbol | ETNB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001785173 |
| CUSIP Number | 282559103 |
| ISIN Number | US2825591033 |
| Employer ID | 83-1114349 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rohan Palekar | Chief Executive Officer & Director |
| Francis W. Sarena | Chief Operating Officer |
| Ryan Stephen Martins | Chief Financial Officer |
| Amanda Kurihara | Vice President of People & Culture |
| Annie J. Chang M.B.A. | Vice President of Investor Relations & Corporate Communications |
| Dr. Harry Mansbach M.D. | Chief Medical Officer |
| Melissa Abel | Senior Vice President of Commercial Strategy |
| Michael Baldwin | Senior Vice President & Head of Quality |
| Quoc Le-Nguyen | Chief Technical Officer |
| Shiva K. Natarajan CPA | Senior Vice President of Finance & Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | 4 | Filing |
| Apr 15, 2025 | ARS | Filing |
| Apr 15, 2025 | DEFA14A | Filing |
| Apr 15, 2025 | DEF 14A | Filing |
| Apr 09, 2025 | 8-K | Current Report |
| Mar 03, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Feb 27, 2025 | S-8 | Filing |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 19, 2025 | 4 | Filing |